Summary: Researchers developed an AI algorithm that, by analyzing brain scans and clinical information, can predict within a week whether an antidepressant will work for patients with major depression disorder. This method could potentially avoid unnecessary prescriptions of sertraline, a commonly used antidepressant, by identifying non-responders early, thus offering better patient care and reducing side effects.
The algorithm focuses on blood flow in the anterior cingulate cortex and symptom severity, marking a significant step towards personalized medicine. This approach not only improves treatment outcomes but also reduces the societal costs associated with prolonged depressive episodes.
Key Facts:
- The AI algorithm can predict antidepressant efficacy up to 8 weeks faster than current methods.
- It correctly identifies one-third of patients as responders to sertraline, significantly reducing incorrect prescriptions.
- The study highlights the importance of tailoring depression treatment to individual patients, potentially revolutionizing the standard care process.
Source: University of Amsterdam
In patients with major depression disorder it is, thanks to use of artificial intelligence, now possible to predict within a week whether an antidepressant will work.
With the help of an AI algorithm, a brain scan and an individual’s clinical information, researchers from Amsterdam UMC and Radboudumc could see up to 8 weeks faster whether or not the medication would work.
The results of this study are published today in the American Journal of Psychiatry.
“This is important news for patients. Normally, it takes 6 to 8 weeks before it is known whether an antidepressant will work,” says Professor of Neuroradiology at Amsterdam UMC, Liesbeth Reneman.
The research team analysed whether they could predict the effect of the antidepressant sertraline, one of the most commonly prescribed drugs in the United States and Europe.
In a previous study conducted in the United States, MRI scans and clinical data were administered to 229 patients with major depression before and after a week of treatment with sertraline or placebo.
The Amsterdam researchers then developed and applied an algorithm to this data to investigate whether they could predict the treatment response to sertraline.
This analysis showed that 1/3 of patients would respond to the drug and in 2/3 not. “With this method, we can already prevent 2/3 of the number of ‘erroneous’ prescriptions of sertraline and thus offer better quality of care for the patient. Because the drug also has side effects,” says Reneman.
The right drug, much faster
“The algorithm suggested that blood flow in the anterior cingulate cortex, the area of brain involved in emotion regulation, would be predictive of the efficacy of the drug. And at the second measurement, a week after the start, the severity of their symptoms turned out to be additionally predictive” says Eric Ruhé, psychiatrist at Radboudumc.
In the future, this new method may help to better tailor sertraline treatment to the individual patient. Currently, there is no exact prediction tool.
The patient is given the medication and after 6 to 8 weeks – in practice often up to several months – it is checked whether the medication works. If the symptoms do not subside, the patient is given another antidepressant, and this process can repeat itself several times.
This standard method often takes weeks, if not months. It also saves society costs, because as long as the patient continues to suffer from the serious depressive symptoms, he or she cannot fully participate in society.
Follow-up examination
In one in three depressed patients, there is still no improvement in the symptoms after several treatment steps. Therefore, there is an urgent need for a solution that allows a faster determination of the effectiveness of antidepressants in severe depression. In the coming period, the researchers will improve the algorithm by adding extra information.
About this AI and psychopharmacology research news
Author: Jack Cairns
Source: University of Amsterdam
Contact: Jack Cairns – University of Amsterdam
Image: The image is credited to Neuroscience News
Original Research: The findings will appear in the American Journal of Psychiatry
